Business Context and Reporting Period
This Form 8-K, dated January 29, 2008, reports a material definitive agreement entered into by Alynx, Co. (the "Registrant") with MiMedx, Inc. and its subsidiary MMX Acquisition Corp. The filing details a planned reverse merger where MiMedx, a development-stage company focused on musculoskeletal therapy products, will become a wholly-owned subsidiary of Alynx. The transaction is expected to close on or about February 8, 2008.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for either Alynx or MiMedx. The document focuses on the structural terms of the merger rather than historical financial performance.
Material Changes and Transaction Terms
- Reverse Merger Structure: MiMedx will merge into a subsidiary of Alynx, with MiMedx continuing as the surviving entity. Alynx will adopt MiMedx's business plan.
- Management Transition: Upon closing, Alynx's sole director/officer will resign, and MiMedx's current officers and directors will be appointed to Alynx.
- Share Exchange Ratios:
- MiMedx common shareholders will receive 3.091421 shares of Alynx common stock for each MiMedx share (approx. 52.3 million new shares).
- MiMedx preferred shareholders will receive 0.2 shares of Alynx Series A Preferred Stock for each MiMedx preferred share (approx. 3.7 million new shares).
- Alynx Series A Preferred Stock is convertible at a rate of 15.45710482 common shares per preferred share.
- Ownership Post-Closing: Existing Alynx shareholders (excluding 20 million shares to be cancelled) will own approximately 2.25% of the post-merger company. MiMedx shareholders, option holders, and warrant holders will own approximately 97.25%.
- Additional Issuances: Alynx intends to issue 636,376 shares to D.H. Blair & Co. for transaction services.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes standard disclaimers that future results may differ materially from expectations due to risks such as the availability of merger candidates, market acceptance of MiMedx products, and the ability to meet financial obligations.
Future Corporate Actions: Post-closing, the new board intends to call a shareholder meeting to propose:
- A reverse stock split of approximately one-for-three for all outstanding classes of capital stock.
- A potential increase in the number of authorized common shares.
Conditions to Closing: The merger is contingent upon approval by a majority of MiMedx's common and preferred stockholders. Alynx stockholder approval is not required.
Investor Verification Checklist
- Verify the final closing date, as the current expectation is "on or about February 8, 2008."
- Confirm the outcome of the MiMedx shareholder vote required to approve the Merger Agreement.
- Review the specific terms of the proposed reverse stock split and the increase in authorized shares once the proxy materials are filed.
- Assess the financial health and product development status of MiMedx, as it will become the primary operating entity.
- Monitor the cancellation of the 20,000,000 shares of Alynx stock currently held by Mr. Edwards.